AI-generated summary
The authors randomized 30 hospitalized patients with COVID-19 and respiratory involvement to high-power photobiomodulation or placebo, both alongside standard treatment. They report that oxygen saturation, respiratory rate, CRP, and IL-6 improved in both groups, with greater CRP, IL-6, and oxygen saturation differences in the photobiomodulation group. The authors recommend the therapy, but the small sample size limits these findings.
- Participants
- 30
- Who or what was studied
- Hospitalized adults with COVID-19 and respiratory involvement during the acute stage
- Limits stated in the abstract
- The abstract does not report the wavelength used and describes only a small sample of 30 participants at a single hospital.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Control group, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.